Marshall Wace North America L.P. increased its position in shares of Teladoc Health Inc (NYSE:TDOC) by 313.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 202,001 shares of the health services provider’s stock after purchasing an additional 153,146 shares during the quarter. Marshall Wace North America L.P. owned 0.29% of Teladoc Health worth $17,443,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of TDOC. Harvest Fund Management Co. Ltd bought a new stake in Teladoc Health during the third quarter worth about $165,000. Signaturefd LLC acquired a new position in Teladoc Health during the third quarter worth about $173,000. Aperio Group LLC acquired a new position in Teladoc Health during the second quarter worth about $201,000. California Public Employees Retirement System acquired a new position in Teladoc Health during the second quarter worth about $203,000. Finally, D.A. Davidson & CO. acquired a new position in Teladoc Health during the third quarter worth about $210,000.
In related news, VP Mark Hirschhorn sold 35,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $80.42, for a total value of $2,814,700.00. Following the sale, the vice president now directly owns 10,000 shares in the company, valued at $804,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Adam C. Vandervoort sold 5,550 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $77.67, for a total value of $431,068.50. Following the completion of the sale, the insider now owns 2,934 shares in the company, valued at $227,883.78. The disclosure for this sale can be found here. Insiders sold 255,929 shares of company stock valued at $17,683,623 in the last ninety days. 3.95% of the stock is currently owned by insiders.
Several research analysts have commented on TDOC shares. Citigroup reissued a “buy” rating and set a $95.00 target price on shares of Teladoc Health in a research note on Friday, September 28th. SunTrust Banks boosted their target price on Teladoc Health to $100.00 and gave the stock a “buy” rating in a research note on Monday, September 24th. KeyCorp boosted their target price on Teladoc Health from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Friday, September 28th. Oppenheimer boosted their target price on Teladoc Health from $68.00 to $89.00 and gave the stock an “outperform” rating in a research note on Friday, September 28th. Finally, Jefferies Financial Group set a $95.00 target price on Teladoc Health and gave the stock a “buy” rating in a research note on Friday, November 2nd. Four research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $85.06.
Teladoc Health stock opened at $53.41 on Friday. Teladoc Health Inc has a 1 year low of $30.88 and a 1 year high of $89.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 8.99 and a quick ratio of 8.99. The company has a market capitalization of $3.91 billion, a PE ratio of -32.37 and a beta of 0.92.
Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Thursday, November 1st. The health services provider reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. Teladoc Health had a negative return on equity of 14.05% and a negative net margin of 31.32%. The company had revenue of $111.00 million during the quarter, compared to the consensus estimate of $109.94 million. During the same quarter in the prior year, the firm posted ($0.55) earnings per share. The firm’s revenue was up 61.6% compared to the same quarter last year. On average, sell-side analysts predict that Teladoc Health Inc will post -1.47 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/12/08/teladoc-health-inc-tdoc-position-raised-by-marshall-wace-north-america-l-p.html.
About Teladoc Health
Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.